Quick Answer
Journey Medical Corp reported Cash And Cash Equivalents At Carrying Value of $24.09 million for the year ending 2025.
- Journey Medical Corp showed an increase of +18.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Journey Medical Corp's annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $41.30 million | Q2 2022: $38.10 million | Q3 2022: $34.89 million | Q1 2023: $17.35 million | Q2 2023: $8.23 million | Q3 2023: $24.75 million | Q1 2024: $24.06 million | Q2 2024: $23.91 million | Q3 2024: $22.46 million | Q1 2025: $21.07 million | Q2 2025: $20.29 million | Q3 2025: $24.95 million.
- Over the full 6 years of available data (2020 to 2025), Journey Medical Corp's Cash And Cash Equivalents At Carrying Value has grown by 192.1%.
- Historical annual values: Fiscal year 2025: $24.09 million | Fiscal year 2024: $20.31 million | Fiscal year 2023: $27.44 million | Fiscal year 2022: $32.00 million | Fiscal year 2021: $49.08 million | Fiscal year 2020: $8.25 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: